Tumori . Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?

[tetano]

Tumori


. 2021 Dec 29;3008916211067825.
doi: 10.1177/03008916211067825. Online ahead of print.
Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?


Giovanna Gattuso ¹ , Elisabetta Schiavello ¹ , Chiara Oltolini ² , Veronica Biassoni ¹ , Monica Terenziani ¹ , Stefano Chiaravalli ¹ , Marta Giorgia Podda ¹ , Cristina Meazza ¹ , Roberto Luksch ¹ , Andrea Ferrari ¹ , Michela Casanova ¹ , Giovanna Sironi ¹ , Luca Bergamaschi ¹ , Nadia Puma ¹ , Filippo Spreafico ¹ , Maura Massimino ¹



Affiliations

• PMID: 34965799
• DOI: 10.1177/03008916211067825

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, oncologists have managed patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments complications from those related to COVID-19. We report a case of an 11-year-old boy undergoing treatment for T-cell lymphoblastic lymphoma who experienced a prolonged COVID-19 course. Oncologic therapy was continued without significant changes compared to the initially planned treatment. No relevant complications occurred. COVID-19 convalescent plasma was administered, resulting in a positive antibody titer after 24 days.

Keywords: COVID-19; lymphoma; prolonged infection; treatments.